EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells

Lei Duan, Mehrdad Jafari Tadi, Kelsey M O'Hara, Carl G Maki

Journal of Biological Chemistry · 2024

DOI: 10.1016/j.jbc.2024.107375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Lei Duan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Lei_Duan@rush.edu. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Defense Peer Reviewed Cancer Research Program, Swim Across America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive breast cancer sub-type with limited treatment options and poor prognosis. Currently, standard treatments for TNBC include surgery, chemotherapy, and anti-PDL1 therapy. These therapies have limited efficacy in advanced stages. Myeloid-cell leukemia 1 (MCL1) is an anti-apoptotic BCL2 family protein. High expression of MCL1 contributes to chemotherapy resistance and is associated with a worse prognosis in TNBC. MCL1 inhibitors are in clinical trials for TNBC, but response rates to these inhibitors can vary and predictive markers are lacking. Currently, we identified a 4-member (AXL, ETS1, IL6, EFEMP1) gene signature (GS) that predicts MCL1 inhibitor sensitivity in TNBC cells. Factors encoded by these genes regulate signaling pathways to promote MCL1 inhibitor resistance. Small molecule inhibitors of the GS factors can overcome resistance and sensitize otherwise resistant TNBC cells to MCL1 inhibitor treatment. These findings offer insights into potential therapeutic strategies and tumor stratification for MCL1 inhibitor use in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Cell Leukemia Sequence 1 ProteinTriple Negative Breast NeoplasmsDrug Resistance, NeoplasmHumansFemaleCell Line, TumorBiomarkers, TumorGene Expression Regulation, NeoplasticAntineoplastic AgentsInterleukin-6Proto-Oncogene Protein c-ets-1

Stichwörter der Autor:innen

AXLEFEMP1ETS1IL6MCL1 inhibitorpredictive markertriple negative breast cancer

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinMCL1 protein, humanBiomarkers, TumorAntineoplastic AgentsETS1 protein, humanInterleukin-6Proto-Oncogene Protein c-ets-1

Autor:innen und Institutionen

  • Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Lei_Duan@rush.edu.
  • Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA.
  • Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: Carl_Maki@rush.edu.

Förderung

  • NCI NIH HHS
  • Department of Defense Peer Reviewed Cancer Research Program
  • Swim Across America
  • U.S. Department of Defense
  • National Institutes of Health

Zitieren

APA

Duan, L., Tadi, M. J., O'Hara, K. M., & Maki, C. G. (2024). Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107375

Vancouver

Duan L, Tadi MJ, O'Hara KM, Maki CG. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107375

BibTeX
@article{Duan2024,
  author = {Duan, Lei and Tadi, Mehrdad Jafari and O'Hara, Kelsey M and Maki, Carl G},
  title = {Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  doi = {10.1016/j.jbc.2024.107375}
}
Kostenlos starten →